mitomycin has been researched along with Peritonitis in 23 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion." | 6.66 | Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1987) |
| "A 71-year-old man with Borrmann type 3 gastric cancer and peritonitis carcinomatosa was treated with 5'-DFUR 600 mg/body p." | 5.30 | [Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa]. ( Ando, S; Katanuma, A; Maekubo, H; Mori, M; Tsuji, K, 1997) |
| "A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion." | 2.66 | Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1987) |
| "Treatment of advanced gastric cancers with peritonitis carcinomatosa is very difficult, because none of the various therapies (operation, chemotherapy, hyperthermia etc." | 1.32 | [A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites]. ( Doi, K; Horiuchi, T; Nakamura, T; Okubo, Y; Shimada, K; Tanabe, S; Tanaka, K; Tanaka, S; Uchinami, M; Yoshida, M, 2004) |
| "Diffuse pyogenic gelatinous ascites and a large cystic mass with a grayish wall, and a hard solid lesion in part were found." | 1.31 | Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case. ( Kuroki, Y; Otagiri, S; Tsukada, K, 2001) |
| "A 71-year-old man with Borrmann type 3 gastric cancer and peritonitis carcinomatosa was treated with 5'-DFUR 600 mg/body p." | 1.30 | [Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa]. ( Ando, S; Katanuma, A; Maekubo, H; Mori, M; Tsuji, K, 1997) |
| "Eighty gastric cancer patients with peritoneal dissemination were analyzed to evaluate the effect of intraperitoneal chemo- and/or immunotherapy on abdominal ascites." | 1.30 | [Effect of intraperitoneal therapy in gastric cancer with peritoneal dissemination]. ( Kajiura, Y; Kondoh, Y; Makuuchi, H; Mitomi, T; Miyaji, M; Nakamura, K; Ogoshi, K; Tajima, T, 1997) |
| "Six patients with gastric cancer and two patients with colon cancer underwent these procedures." | 1.29 | [Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer]. ( Fujimura, T; Fujita, H; Fushida, S; Hirono, Y; Itoh, H; Kaji, M; Kinami, S; Nakagawara, H; Nakai, M; Yonemura, Y, 1995) |
| " The dosage was 14 mg/m2 (7 mg/m2 at second and following administrations) of MMC and 35 mg/m2 of CDDP and they were repeatedly administered in the abdominal cavity via the drug delivery system." | 1.29 | [Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis]. ( Arai, K; Kitamura, M; Miyashita, K, 1993) |
| " Pharmaceutical dosage was set at approximately 30% of the increased life span (ILS) for Meth-A." | 1.28 | [Experimental study of the treatment of carcinomatous peritonitis in gastric cancer]. ( Arai, K; Kitamura, M; Miyashita, K, 1992) |
| "Because the subjects studied were gastric cancer cases exceeding H2, the present investigation resulted in the increase of metastatic liver lesions, a problem to be studied in future." | 1.28 | [CDDP-ip PMUE therapy in gastric cancer cases with liver metastasis]. ( Hasegawa, Y; Honnma, S; Nakashima, Y; Takanashi, K; Yajima, K, 1991) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 16 (69.57) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akamo, Y | 1 |
| Takeyama, H | 1 |
| Funahashi, H | 1 |
| Yamamori, Y | 1 |
| Yamamoto, M | 1 |
| Teranishi, F | 1 |
| Manabe, T | 1 |
| Aihara, H | 1 |
| Maruoka, H | 1 |
| Kiyozaki, H | 1 |
| Konishi, F | 1 |
| Nakamura, T | 1 |
| Shimada, K | 1 |
| Okubo, Y | 1 |
| Tanaka, S | 1 |
| Tanabe, S | 2 |
| Yoshida, M | 1 |
| Doi, K | 1 |
| Uchinami, M | 1 |
| Horiuchi, T | 1 |
| Tanaka, K | 1 |
| Takahashi, T | 2 |
| Hagiwara, A | 2 |
| Ito, T | 1 |
| Fujimura, T | 1 |
| Yonemura, Y | 1 |
| Nakagawara, H | 1 |
| Fujita, H | 1 |
| Itoh, H | 1 |
| Hirono, Y | 1 |
| Kinami, S | 1 |
| Kaji, M | 1 |
| Nakai, M | 1 |
| Fushida, S | 1 |
| Gallinaro, RN | 1 |
| Naziri, W | 1 |
| McMasters, KM | 1 |
| Peyton, JC | 1 |
| Cheadle, WG | 1 |
| Kitamura, M | 4 |
| Arai, K | 4 |
| Iwasaki, Y | 2 |
| Miyashita, K | 2 |
| Kosaka, T | 1 |
| Takano, Y | 1 |
| Nakano, Y | 1 |
| Akiyama, T | 1 |
| Kiriyama, M | 1 |
| Tomita, F | 1 |
| Saito, H | 1 |
| Kita, I | 1 |
| Takashima, S | 1 |
| Nakagawa, T | 1 |
| Matsui, R | 1 |
| Kashihara, K | 1 |
| Higashi, T | 1 |
| Seo, K | 1 |
| Taoka, Y | 1 |
| Yoshida, S | 1 |
| Nishitani, H | 1 |
| Takegawa, Y | 1 |
| Hukumura, Y | 1 |
| Ando, S | 2 |
| Katanuma, A | 1 |
| Mori, M | 1 |
| Tsuji, K | 1 |
| Maekubo, H | 1 |
| Kajiura, Y | 1 |
| Ogoshi, K | 1 |
| Nakamura, K | 1 |
| Miyaji, M | 1 |
| Kondoh, Y | 1 |
| Makuuchi, H | 1 |
| Tajima, T | 1 |
| Mitomi, T | 1 |
| Takayanagi, N | 1 |
| Danjo, Y | 1 |
| Kuroki, Y | 1 |
| Otagiri, S | 1 |
| Tsukada, K | 1 |
| Sugiyama, Y | 1 |
| Saji, S | 1 |
| Furuta, T | 1 |
| Azuma, S | 1 |
| Miya, K | 1 |
| Umemoto, T | 1 |
| Takao, H | 1 |
| Kato, M | 1 |
| Kanno, A | 1 |
| Konno, C | 1 |
| Fujimoto, S | 1 |
| Shrestha, RD | 1 |
| Kokubun, M | 1 |
| Kobayashi, K | 1 |
| Kiuchi, S | 1 |
| Takahashi, M | 1 |
| Ohta, M | 1 |
| Hasegawa, Y | 1 |
| Honnma, S | 1 |
| Takanashi, K | 1 |
| Yajima, K | 1 |
| Nakashima, Y | 1 |
| Yamada, Y | 1 |
| Nakatani, K | 1 |
| Watanabe, A | 1 |
| Sawada, H | 1 |
| Yano, T | 1 |
| Shino, Y | 1 |
| Nakano, H | 1 |
| Tsuji, Y | 1 |
| Nishimura, A | 1 |
| Katsuki, Y | 1 |
| Yasuda, T | 1 |
| Lee, R | 1 |
| Ueda, T | 1 |
| Takeda, M | 1 |
| Itoh, T | 1 |
| Ishibashi, H | 1 |
| Hirakawa, K | 1 |
| Nakajima, H | 1 |
| Ioka, J | 1 |
| Shirono, K | 1 |
| Ochiai, K | 1 |
| Tomita, K | 1 |
| Kitagawa, Y | 1 |
2 trials available for mitomycin and Peritonitis
| Article | Year |
|---|---|
[Evaluation of intraperitoneal chemotherapy using CDDP combined with MMC in gastric carcinomatous peritonitis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fe | 1994 |
Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials.
Topics: Charcoal; Clinical Trials as Topic; Dosage Forms; Female; Humans; Microscopy, Electron; Middle Aged; | 1987 |
21 other studies available for mitomycin and Peritonitis
| Article | Year |
|---|---|
[Efficacy of intraperitoneal chemotherapy for advanced Borrmann type IV gastric carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infus | 2002 |
Sclerosing encapsulating peritonitis (SEP) as a delayed complication of continuous hyperthermic peritoneal perfusion (CHPP): report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2003 |
[A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Drug Administrati | 2004 |
[Intraabdominal administration of MMC adsorbed on activated carbon for management of carcinomatous peritonitis].
Topics: Abdomen; Carbon; Colonic Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Mitomyc | 1984 |
[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined | 1995 |
Alteration of mononuclear cell immune-associated antigen expression, interleukin-1 expression, and antigen presentation during intra-abdominal infection.
Topics: Abdominal Abscess; Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antigen Presentation; Flow Cytometry; | 1994 |
[Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
[Intraarterial infusion chemotherapy for recurrent or unresectable gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 1993 |
[A case of recurrent squamous cell carcinoma of cervix successfully treated with BOMP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fema | 1996 |
[Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Sc | 1997 |
[Evaluation of intraperitoneal chemotherapy using CDDP/MMC or CDDP for gastric carcinomatous peritonitis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Humans; Inf | 1997 |
[Effect of intraperitoneal therapy in gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Female; Humans; Immunity | 1997 |
[A case of gastric cancer with peritonitis carcinomatosa and malignant biliary stenosis treated by intraperitoneal CDDP and MMC with UFT therapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract | 1998 |
Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Diagn | 2001 |
[Experimental study of the treatment of carcinomatous peritonitis in gastric cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Infusions, Parente | 1992 |
[Clinical studies on locoregional immunochemotherapy of peritonitis carcinomatosa].
Topics: Cisplatin; Humans; Immunotherapy; Infusions, Parenteral; Mitomycin; Pancreatic Neoplasms; Peritoniti | 1992 |
[Clinical evaluation of intra-peritoneal hyperthermic perfusion under hypothermic general anesthesia for advanced gastric cancer].
Topics: Anesthesia, General; Combined Modality Therapy; Female; Gastrectomy; Humans; Hyperthermia, Induced; | 1991 |
[CDDP-ip PMUE therapy in gastric cancer cases with liver metastasis].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1991 |
[Enhancement of the carcinomatous peritonitis of human gastric cancer by pretreatment of mitomycin C in nude mice: preliminary report].
Topics: Animals; Cell Division; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplan | 1991 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
[A case of gastric cancer with peritonitis carcinomatosa which improved upon oral administration of UFT, mitomycin C and lentinan].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1987 |